北米の精神科/うつ病市場における薬理遺伝学検査 – 2029年までの業界動向と予測

北米の精神医学/うつ病における薬理遺伝学検査市場の分析と洞察

薬理遺伝子検査は、人が薬剤をどのように代謝するかに関する情報を提供することで、医療専門家の役に立ちます。この情報は、医師やその他の関係者が望ましくない結果をもたらす可能性のある抗うつ薬の処方を避けるのに役立ちます。薬理遺伝子学は、大うつ病性障害 (MDD) の治療における抗うつ薬の反応と忍容性を予測する上で有望であることが示されています。薬理遺伝子学は、抗うつ薬の選択と投与量を導くことで臨床結果を改善できます。バイオテクノロジー分野の成長と医療費の増加により、精神医学/うつ病における薬理遺伝子検査の需要が加速しています。

癌の罹患率の増加、うつ病やその他の精神疾患の治療における新技術により、精神科/うつ病の機器や処置における薬理遺伝学 検査の採用が増加しており、非外科的処置に対する好みが高まっていることが、予測期間中の市場の需要を押し上げる主な要因となっています。ただし、検査に関連する高コスト、厳格な規制、認識不足により、予測期間中の精神科/うつ病市場における薬理遺伝学検査の成長が妨げられる可能性があります。

Data Bridge Market Research は、北米の精神医学/うつ病における薬物遺伝学検査市場は、予測期間中に 9.7% の CAGR で成長し、2029 年までに 9 億 8,128 万米ドルに達すると予測しています。北米の人口におけるうつ病率の上昇により、不安障害が市場で最大のタイプ セグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

North America Pharmacogenetics Testing in Psychiatry/Depression Market Definition

Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.

The terms personalized medicine, stratified medicine, and precision medicine are close relatives of pharmacogenetics, but these are broader terms that also cover additional non-genetic factors. Nevertheless, pharmacogenetics is an important component of these areas. Pharmacogenetics is primarily concerned with human germline DNA variation, but there have also been important recent advances in understanding mood disorders, and mental illnesses.

Pharmacogenetics testing studies the interaction between drug and gene response of a person and searches for the gene variation which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights which subsequently be used to develop customized or personalized medication.

North America Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER

Depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Depression can become a serious health condition of mild to extreme severity, affecting the person to suffer greatly and can lead to suicide in the worst cases. Although over 45 antidepressants are available, suboptimal response poses a challenge and is considered a result of genetic variation, psychiatry/depression. Depending on the severity and pattern of depressive episodes over time, healthcare providers may offer psychological diagnosis such as behavioral activation, cognitive behavioral therapy, interpersonal psychotherapy, and/or antidepressant medication such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Different drugs are used for this kind of mental disorder.

With the growth in the prevalence of depression, the demand for pharmacogenetics testing is also increasing as it studies the effect of genetic variants intending to furnish tailored diagnosis. The market is expected to grow in foresting period.

• RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE

Pharmacogenetics test aids the medical professional in choosing the best medicine for the person because the test searches for the gene variant that may be responsible for influencing the effect of the drug.

Medicine is beginning to get personal, and patients are gradually expressing interest in improved outcomes and less adverse effects with personalized medications. Personalized medicine has the potential to tailor the therapy with a high safety margin and the best response. This trend is largely driven by genome sequencing improvements.

The move toward personal healthcare means changes in the manufacturing of medicines. Manufacturers are moving from creating small molecules to the combination of small molecule and gene therapies. Sponsors focus on replacing inefficient large-scale batch production with investment in new technology and producing personalized drugs.

Restraint

• Lack of skilled Medical and genomic expert 

Most clinicians still lack confidence in pharmacogenetic (PGx) testing and subsequent data interpretation, indicating insufficient knowledge in this field. It emphasizes the need to improve literacy among healthcare professionals regarding expertise in and understanding of pharmacogenetic (PGx) testing.

Lack of practitioners awareness about the possibilities of pharmacogenetics and poor or insufficient explanation of the test results also reduce personalization technologies for patients. In addition to developing thematic training courses at medical universities, including the educational cycles in continuing professional education systems, and free placement of information for practicing doctors are required: academic internet portals, webinars, etc. A clinical pharmacologist plays a crucial role in the implementation of pharmacogenetic testing.

The competence of a clinical pharmacologist in the field of pharmacogenetics is critical: he or she is the one who organizes the application of genotyping in clinical practice, interprets tests, and informs doctors about the possibilities of pharmacogenetics for patients with specific nosologies, that is, acts as the main link between the scientific world, the healthcare system and practicing physicians in the process of introducing pharmacogenetics.

Opportunity

• Rising advancements in technology

Advances in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice for psychiatric disorders. Personalized medicine may be defined as a comprehensive, prospective approach to preventing, diagnosing, treating, and monitoring disease in ways that achieve optimal individual health care decisions. Over 100 medications now contain United States Food and Drug Administration (FDA) labelling related to potentially applicable pharmacogenomic biomarkers with technological advancements in healthcare. Also, new and advanced methods are being developed to promote pharmacogenetics testing in depression-like disorders. These tests use advanced genetic testing methods to give precise results to form a treatment regimen. The improvements in technology supporting tests improved accessibility of testing options, and the growing number of resources that help clinicians understand how to use this information when it is available are making this aspect of personalized or precision medicine a reality. Thus,  providers need to become more aware of the scientific and clinical relevance of pharmacogenomic tests.

The tests also help to establish a meaningful relationship between a drug and the individual genetic makeup. This helps in deciding the drugs to be administered to the patient to treat major depressive disorders and other psychiatric conditions.

Challenge

• Strict government regulation on new products and instruments approval

The concerns regarding the efficacy and safety of products have caused most governments to develop regulatory agencies and policies to look after the development of new medical products or tests. The use of these medical products can be done after passing stringent regulatory standards, which ensure the product is safe, well studied, and has no adverse reactions.

The recent guidelines and the amendment have adequate guidance for manufacturers. International regulations such as food, drug, and administration play a major role in the new launch of medical products or test into the market. Thus, it can be a major restraint for the market. Therefore, strict government regulation on new products and instrument approval will likely impact the market.

Post-COVID-19 Impact on North America pharmacogenetics testing in psychiatry/depression market

The COVID-19 outbreak had a beneficial impact on the expansion of the pharmacogenetics testing industry. The pandemic has had a negative impact on the pharmacogenomics market growth on account of the temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers. Since the second half of 2020, with the rising demand for research on certain drugs and testing kits for COVID-19, pharmacogenomic practices have been in vogue.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.

Recent Developments

• In April 2022, Blue Care Network (BCN) launched a precision medicine program, Blue Cross Personalized Medicine, which leverages pharmacogenomics, or genetic testing, to personalize and tailor medication treatments more effectively for select members based on a review of their prescribed medications for various diagnosis including behavioral health, cardiology, cardiovascular, and oncology. OneOme LLC has helped BCN achieve its precision medicine program goals and reduce the total cost of care and improve patient health outcomes by reducing adverse drug reactions. This has helped the company to enhance its product portfolio.
• In February 2022, PacBio, a leading provider of high-quality, highly accurate sequencing platforms, announced that it is supporting The Hospital for Sick Children (SickKids) in Toronto, Canada, in using HiFi whole genome sequencing (HiFi WGS) to potentially identify genetic variants that may be associated with medical and developmental conditions. Samples that are examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology but still lack the identification of a disease-causing variant. This has helped the company to enhance the use of its products.
• In July 2022, according to a new nationwide study of nearly 2,000 veterans conducted by the U.S. Department of Veterans Affairs (VA), and Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight Psychotropic test results from Myriad Genetics, Inc. in largest ever mental health PGx randomized controlled trial. This has helped the company to show its progress in pharmacogenetic testing.
• In January 2021, myDNA Life Australia Pty Ltd, announced a merger with the U.S., Houston-based consumer DNA test company, FamilyTreeDNA, and its parent company, Gene by Gene, for revolutionizing the field of pharmacogenomics, making truly personalized medicine a reality before expanding into nutrigenomics to deliver actionable, personalized nutrition, fitness and skincare recommendations. This has helped the company to expand its business.

 North America Pharmacogenetics Testing in Psychiatry/Depression Market Scope

North America pharmacogenetics testing in psychiatry/depression market is segmented into type, test type, gene type, patient type, product, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Type
  • Anxiety
  • Mood Disorders
  • Depression
  • Bipolar Disorders
  • Psychotic Disorders
  • Eating Disorders

On the basis of type, North America pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type
  • Whole Genome Sequencing
  • Chromosomal Array-Based Tests

On the basis of test type, North America pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Gene Type
  • CYP2C19
  • CYP2C9 AND VKORC1
  • CYP2D6
  • HLA-B
  • HTR2A/C
  • HLA-A
  • CYP3A4
  • SLC6A4
  • MTHFR
  • COMT
  • OTHERS

On the basis of gene type, North America pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type
  • Child
  • Adult
  • Geriatric

On the basis of patient type, the North America pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatrics.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Product
  • Instruments
  • Consumables
  • Software & Services

On the basis of product type, North America pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By End User
  • Hospitals & Clinics
  • Dignostics Laboratories
  • Academic And Research Institutes
  • Others

On the basis of end user, North America pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Distribution Channel
  • Direct Tender
  • Third-Party Distribution
  • Hospital Pharmacy
  • Others

On the basis of distribution channel, the North America pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third-party distribution hospital pharmacy, and others.

North America Pharmacogenetics Testing in Psychiatry/Depression Market Regional Analysis/Insights

The North America pharmacogenetics testing in psychiatry/depression market is analyzed, and market size information is provided by the type, test type, gene type, patient type, product, end user, and distribution channel. The countries covered in this market report are the U.S., Canada, and Mexico.

In 2022, North America is dominating due to the presence of key market players in the largest consumer market with high GDP. The U.S is expected to grow due to the rise in technological advancement in pharmacogenetics testing.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape And North America Pharmacogenetics Testing In Psychiatry/Depression Market Share Analysis

North America pharmacogenetics testing in psychiatry/depression market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America pharmacogenetics testing in psychiatry/depression market.

Some of the major players operating in the North America pharmacogenetics testing in psychiatry/depression market are

• Genelex (Part of Invitae corporation)
• Genewiz (Part of Azenta Life Sciences)
• MD Labs
• BiogeneiQ, Inc.
• ONEOME, LLC
• Myriad Genetics, Inc.
• GenXys
• Castle Biosciences, Inc.
• PacBio
• QIAGEN
• Thermo Fisher Scientific Inc.
• AB-Biotics.S.A. 
• Coriell Life Sciences
• Eurofins Scientific
• Illumina, Inc.
• Dynamic DNA Laboratories
• STADAPHARM GmbH
• Color
• Cnsdose
• Genomind, Inc.
• Healthspek
• myDNA Life Australia Pty Ltd.
• HudsonAlpha
• Sonic Healthcare Limited

調査方法: 北米の精神科/うつ病市場における薬理遺伝学検査

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、北米と地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。

SKU-60339